Table 4 Incremental cost-effectiveness ratio (per patient)
FOLFOX4 | Sorafenib | Incremental | |
|---|---|---|---|
Discounted | |||
Drug costs | US$ 6972 | US$ 12,289 | − US$ 5317 |
General ward costs | US$ 145 | US$ 0 | US$ 145 |
AE costs | US$ 69 | US$ 4 | US$ 64 |
Tests | US$ 1242 | US$ 504 | US$ 738 |
Total costs | US$ 8428 | US$ 12,798 | − US$ 4371 |
QALY | 0.42 | 0.38 | 0.034 |
FOLFOX4 dominance | |||